Welcome to our dedicated page for Genvor news (Ticker: GNVR), a resource for investors and traders seeking the latest updates and insights on Genvor stock.
Genvor Inc. develops AI-assisted peptide discovery technology for agriculture, health and wellness applications. Company news centers on its BioCypher platform, peptide research, sustainable crop-protection technology, human wellness expansion, commercialization partnerships and executive business-development appointments.
Recurring updates include peer-reviewed validation of AGM182 antifungal peptide technology, research collaborations, conference presentations and strategic commercialization frameworks. News also covers Genvor's movement from agriculture-focused peptide programs into broader health, recovery, performance and wellness categories.
Genvor (OTCID: GNVR) regained active OTCQB trading status on October 9, 2025, positioning the company to accelerate capital formation as it scales field trials and commercialization efforts.
The company said it now operates a newly opened laboratory in Woodland, California to support R&D for foliar and peptide-based formulations, and it is advancing four international research collaborations across Europe, Brazil, and the United States focused on peptide-based seed traits and foliar applications.
Management highlighted that these developments support product validation, global field trials, and expanded scientific capabilities for sustainable agriculture.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.